Acute Opioid Receptor Blockade Restores Vascular Endothelial Growth Factor and Astrocyte Response in db/db Mouse Brain Following Hypoxia-Ischemic Injury

Journal of Neuroscience Research April 2026  Acute Opioid Receptor Blockade Restores Vascular Endothelial Growth Factor and Astrocyte Response in db/db Mouse Brain Following Hypoxia-Ischemic Injury Rashmi Kumari, Elizabeth A Proctor & Patricia McLaughlin Abstract Diabetes plays an important role in the pathogenesis of ischemic stroke and brain recovery. We have reported the neuroprotective effect of […]

Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician’s Practice

Journal of Pain Research, Volume 18 Authors: Hannah Aalto, Sara Paul & Virginia McEwen Published 10 December 2025 Volume 2025:18 Pages 6637—6649 https://www.dovepress.com/real-world-effectiveness-and-tolerability-of-low-dose-naltrexone-to-tr-peer-reviewed-fulltext-article-JPR Purpose: Low-dose naltrexone (LDN) is an off-label treatment for chronic pain, with evidence supporting its use mainly consisting of small-scale studies. This retrospective cohort review aimed to contribute to this growing body […]

Low dose naloxone mitigates opioid tolerance and dependence and restores mesenchymal stem cell function for cell therapy in addiction

Article, Open access, Published: 03 October 2025 Low dose naloxone mitigates opioid tolerance and dependence and restores mesenchymal stem cell function for cell therapy in addiction Maryamossadat Mirtajaddini Goki, Azadeh Rostamgohary, Sara Yaghoubi, Khadijeh Esmaelipour Bezenjani, Zahra Behroozi, Mohammad-Erfan Norouzmahani, Mohammad Samani, Mohammad Hadi Nematollahi & Mehrnaz Mehrabani.  Scientific Reports volume 15, Article number: 34494 (2025)  Abstract The […]

Evaluation of Low-Dose Naltrexone for Chronic Pain Management

Evaluation of Low-Dose Naltrexone for Chronic Pain Management February 2025 Journal of Pain & Palliative Care Pharmacotherapy  Alexa Spargo, Lauren Gonser & Brittany Faley https://www.researchgate.net/publication/388679440_Evaluation_of_Low-Dose_Naltrexone_for_Chronic_Pain_Management Abstract Naltrexone is an opioid antagonist approved by the Food and Drug Administration (FDA) for alcohol use disorder and opioid use disorder. More recently, naltrexone has been used off-label at […]

Co-administration of low-dose-Naltrexone and Carbamazepine remarkedly ameliorate allodynia and cognitive deficit in a rat model of trigeminal neuralgia

Co-administration of low-dose-Naltrexone and Carbamazepine remarkedly ameliorate allodynia and cognitive deficit in a rat model of trigeminal neuralgia Yeganeh Naderi, Monavareh Soti, Masoud Soltani, Yasaman Naderi, Kristi A. Kohlmeier & Mohammad Shabani Scientific Reports volume 15, Article number: 31335 (26th August 2025) https://www.nature.com/articles/s41598-025-14820-4 Abstract The aim of this study was to examine the pain-relieving effects […]

Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance

Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance By Hoau-yan Wang 2009, Opiate Receptors and Antagonists https://www.academia.edu/18459676/Ultra_Low_Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerance?email_work_card=view-paper Ultra-low-dose opioid antagonists have been shown to enhance opioid analgesia and attenuate the tolerance to analgesic effects normally seen with chronic opioid administration. This chapter reviews the early work with ultralow-dose opioid antagonists starting with electrophysiological recordings […]

Low-Dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients

ORIGINAL RESEARCH article Front. Mol. Biosci., 19 May 2025 Sec. Molecular Diagnostics and Therapeutics Volume 12 – 2025 | https://doi.org/10.3389/fmolb.2025.1582967 Low-Dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients Etianne Martini Sasso, Natalie Eaton-Fitch, Peter Smith, Katsuhiko Muraki & Sonya Marshell-Gradisnik Introduction: Long COVID is a multisystemic condition that […]

Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia

Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia Zapata N, Georgiadi E, Cantrell C, et al. (June 22, 2025) Cureus 17(6): e86538. doi:10.7759/cureus.86538 Abstract Introduction  Low-dose naltrexone (LDN) has been studied in recent years as a novel off-label therapy for several conditions under the umbrella of dysautonomia, which is defined as […]

Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review

Research Open access  Published: 22 May 2025 Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review Yu Bin Seo, Yu Jung Choi, Jun-Won Seo, Eun Jung Kim, Jacob Lee & Joon Young Song  BMC Infectious Diseases volume 25, Article number: 731 (2025)  https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-11131-x Abstract Objectives This scoping review aimed to summarize the […]

Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up

Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up Ulrich Moser | Published: May 10, 2025 https://www.cureus.com/articles/366372-low-dose-naltrexone-for-severe-fibromyalgia-syndrome-a-report-of-a-case-with-two-year-follow-up#!/ Abstract Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and often further somatic symptoms. While some patients with FMS respond to standard treatment with […]